0001104659-24-051640.txt : 20240425 0001104659-24-051640.hdr.sgml : 20240425 20240425080626 ACCESSION NUMBER: 0001104659-24-051640 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240419 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240425 DATE AS OF CHANGE: 20240425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STANDARD BIOTOOLS INC. CENTRAL INDEX KEY: 0001162194 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 770513190 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34180 FILM NUMBER: 24873087 BUSINESS ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502666000 MAIL ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: FLUIDIGM CORP DATE OF NAME CHANGE: 20011113 8-K 1 tm249061d2_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 19, 2024

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-34180		77-0513190
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

2 Tower Place, Suite 2000

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 266-6000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		LAB		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.05.

Costs Associated with Exit or Disposal Activities.

On April 25, 2024, Standard BioTools Inc. (the “Company”) announced a reduction-in-force of approximately 10% of its total workforce, including the elimination of certain senior management positions following the closing of the Company’s merger with SomaLogic, Inc., as part of an operational restructuring plan. The purpose of the restructuring plan, including the reduction-in-force, is to improve operational efficiency and reduce operating costs, while supporting the execution of the Company’s long-term strategic plan.

The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be in the range of approximately $10 million to $11 million, which includes approximately $4 million of non-cash expenses related to vesting of share-based awards. The Company expects these costs to be payable over the next three quarters. These estimates are subject to a number of assumptions, and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the operational restructuring plan, including the reduction-in-force.

Item 7.01.

Regulation FD Disclosure.

On April 25, 2024, the Company issued a press release announcing the operational restructuring plan, including the reduction-in-force. A copy of the press release is furnished hereto as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by reference in any filing under the Exchange Act, or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such future filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the expected costs and timing associated with reduction-in-force and expected reductions of operating expenses. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to cost reduction efforts. In addition, the Company’s costs may be greater than anticipated and the workforce and operating expense reductions may have an adverse impact on the Company’s sales and development activities. Additionally, these forward-looking statements should be considered in conjunction with the cautionary statements and risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings filed from time to time with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statement, except as required by law.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Standard BioTools Inc. Press Release dated April 25, 2024.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Standard BioTools Inc.

Date: April 25, 2024	By:	/s/ Jeffrey Black
		Jeffrey Black
		Chief Financial Officer

2

EX-99.1 2 tm249061d2_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

	·	Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025
	·	Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call

South San Francisco, Calif., April 25, 2024 -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while supporting the execution of the Company’s long-term strategic plan.

“Following the completion of the SomaLogic merger, our management team has conducted a comprehensive review of our business as we continue to execute our strategic growth plan. Today we are taking critical and proactive steps to optimize our cost structure, which reflects the Company’s commitment to accelerate our path to profitability and achieve our long-term financial targets,” said Michael Egholm, PhD, President and CEO of Standard BioTools. “We will continue to focus on disciplined expense management while staying true to our mission of becoming a diversified leader in life sciences tools and empowering our customers to do better world-changing research.”

The restructuring plan is expected to generate annualized operating expense savings of $45 million to $50 million in fiscal 2025, with the majority of the cost takeout to occur in the second half of 2024. The plan focuses on two core areas:

·

Workforce Reduction: The Company has implemented a reduction of approximately 10% of its total workforce to better align the Company’s personnel costs with the current needs of its business. This includes the elimination of certain senior management positions following the closing of the SomaLogic merger. The Company expects expenses related to these reductions in the range of $10 million to $11 million, consisting primarily of cash severance and termination benefits and related costs, and includes approximately $4 million of non-cash expenses related to vesting of share-based awards.

·

Streamlined Operational Expenditures: Includes reductions in overall selling, general and administrative (SG&A) expenses, the closure of the Company’s R&D facility in San Diego, as well as savings related to a more prioritized R&D strategy.

Egholm continued, “We value the immense contributions of our colleagues and I want to express my sincere gratitude to the members of our team who will be departing Standard BioTools. These changes, while difficult, are necessary to support our business as we continue to build the broadest next generation of solutions serving the proteomics customer end market.”

First Quarter 2024 Earnings Conference Call Information

Standard BioTools will host a conference call and webcast on Wednesday, May 8, 2024 at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss first quarter 2024 financial results, operational progress and provide additional detail on today’s announcement. Live audio of the webcast will be available online along with an archived version of the webcast under the Events & Presentations page of the Company’s website.

To participate in the conference call by phone, may do so using one of the following dial-in numbers below:

US domestic callers: 1-888-346-3970

Outside US callers: 1-412-902-4297

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance; expectations, operational and strategic plans; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits of the Company’s operational restructuring plan, including the potential for it to drive long-term profitable growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits of the operational restructuring plan, including the potential for it to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from this restructuring, including the anticipated decrease in operational expenses, at the levels it expects; possible restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; restructuring activities, including the Company’s subleasing plans, customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the SEC on March 1, 2024, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter^®, Facebook^®, LinkedIn, and YouTube^TM. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Available Information

Standard BioTools uses its website (standardbio.com), investor site (investors.standardbio.com), corporate X account (@Standard_BioT), Facebook page (facebook.com/StandardBioT), and LinkedIn page (linkedin.com/company/standard-biotools) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools’ website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts.

Investor Contact

David Holmes

Gilmartin Group LLC

(332) 330-1031

ir@standardbio.com

EX-101.SCH 3 lab-20240419.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lab-20240419_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lab-20240419_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 19, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 19, 2024
Entity File Number	001-34180
Entity Registrant Name	Standard BioTools Inc.
Entity Central Index Key	0001162194
Entity Tax Identification Number	77-0513190
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2 Tower Place
Entity Address, Address Line Two	Suite 2000
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	266-6000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	LAB
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://standardbio/role/Cover Cover Cover 1 false false All Reports Book All Reports lab-20240419.xsd lab-20240419_lab.xml lab-20240419_pre.xml tm249061d2_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm249061d2_8k.htm": { "nsprefix": "LAB", "nsuri": "http://standardbio/20240419", "dts": { "schema": { "local": [ "lab-20240419.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lab-20240419_lab.xml" ] }, "presentationLink": { "local": [ "lab-20240419_pre.xml" ] }, "inline": { "local": [ "tm249061d2_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://standardbio/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm249061d2_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm249061d2_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-051640-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-051640-xbrl.zip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�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end XML 17 tm249061d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001162194 2024-04-19 2024-04-19 iso4217:USD shares iso4217:USD shares false 0001162194 8-K 2024-04-19 Standard BioTools Inc. DE 001-34180 77-0513190 2 Tower Place Suite 2000 South San Francisco CA 94080 650 266-6000 false false false false Common Stock, $0.001 par value per share LAB NASDAQ false